Randomized controlled trial confirms that Impella CP(R) improves survival in patients with ST-segment elevation myocardial infarction accompanied by cardiogenic shock
*View in browser* *Japan Abiomed*
Press release: April 11, 2024
**
Randomized controlled trial confirms that Impella CP(R) improves survival in patients with ST-segment elevation myocardial infarction accompanied by cardiogenic shock
Danvers, Massachusetts April 7, 2024 – American College of Cardiology Cardiology), and was simultaneously published in the New England Journal of In a new clinical trial published in Medicine, Impella was used in patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock.
It was confirmed that the CP group had a 12.7% reduction in 180-day mortality compared to the control group (45.8% vs. 58.5%, p=0.04). Danish German Cardiogenic Shock (DanGer
Shock) Randomized Controlled Trial (RCT) was the first randomized controlled trial of a mechanical circulatory support device to demonstrate its effect on the survival outcomes of patients with cardiogenic shock caused by acute myocardial infarction. The trial enrolled 360 people at 14 sites in Denmark, Germany, and the United Kingdom between 2013 and 2023 (1).
“I would like to extend my heartfelt congratulations to Dr. Moller and the group of investigators who initiated and completed this landmark trial. What impressed me most was the impact of the Impella group compared to the control group. “The effect on life prognosis is increasing over time,” said Abiomed Executive.
said Dr. Chuck Simonton, Vice President and Chief Medical Officer.
Approximately 750,000 people in the United States develop STEMI each year (2), and the incidence of cardiogenic shock in STEMI patients is up to 10%.
It is (3). Cardiogenic shock is considered the main cause of in-hospital mortality in STEM patients (4).
The authors believe that the increased risk of adverse events does not undermine the benefits of treatment with Impella CP.
*About Abiomed*
Abiomed, based in Danvers, Massachusetts, is part of the Johnson & Johnson MedTech division and is a leading manufacturer of circulatory support and oxygenation devices. Our products aim to improve hemodynamics and provide sufficient oxygen to patients suffering from respiratory failure, reducing the burden on the heart muscle and helping them recover. For more information
Visit https://www.abiomed.com.
* About Johnson & Johnson Medtech*
johnson & johnson
Medtech leverages our diverse medical and healthcare expertise, valuable technology, and passion for people to transform the future of medicine and help people live their best lives. . For more than a century, we have used the power of science-based innovation to address unmet needs and reimagine health care.
We continue to lead the future of smarter, less invasive, and personalized healthcare solutions to save lives in general surgery, orthopedics, and cardiology. To go. For more information
Visit https://thenext.jnjmedtech.com.
*Forward-looking statements*
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding Impella CP and Impella CP with SmartAssist. The reader is cautioned not to rely on these forward-looking statements . These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of A biomed, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither Abiomed, Inc.., nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
This press release is a Japanese translation of the English press release issued by Abiomed of the United States on April 7, 2024 local time. The official language is English, and some content does not apply to Japan. English is preferred for interpretation.
https://www.abiomed.com/about-us/news-and-media/press-releases/rct-confirms-impella-cp-improves-survival-in-heart-attack-with-cs
The official version of this press release is the original language version. Translated language versions are provided for the convenience of the reader and have no legal effect. When using a translated language version as a document, please compare it with the original language version, which is the only legally enforceable version.
contact information
Jenny Leary
Associate Director, US Communications
jleary@abiomed.com
978-882-8491
1. Moller, et al., New England Journal of Medicine, 7 Apr 2024 2. Abe, et al., Journal of the American Heart Association, 27 Feb 2023. 3. Kolte, et al., Journal of the American Heart Association, 13 Jan 2014
4. Cosentino, et al., Journal of Clinical Medicine, 21, May, 2021 *About details about this release*
https://prtimes.jp/main/html/rd/p/000000008.000048675.html
*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=48675&release_id=8
Copyright © PR TIMES Corporation All Rights Reserved.